

JDRF Industry Discovery & Development Partnerships

JDRF has committed over \$1.3 billion to its research mission to accelerate the discovery, development, and delivery of disease-modifying therapeutics and devices to better treat and cure type 1 diabetes and its complications.

Purpose of JDRF Industry Discovery & Development Partnerships (IDDP) Program

The IDDP Program seeks meaningful relationships with biotech and pharmaceutical partners focused on the discovery, development, and commercialization of therapeutics and devices for type 1 diabetes and its complications. JDRF industry funding can support research programs in companies, publicly or privately held, focused on our core research and strategic therapeutic objectives:

- Restore pancreatic beta cell function by regenerating beta cells
- Restore pancreatic beta cell function by beta cell replacement
- Reverse autoimmunity and restore immunoregulation
- Restore metabolic control
- Prevent and reverse diabetic complications
- Development of biomarkers linked to beta cell mass/regeneration, islet inflammation, and progression of diabetic complications


JDRF particularly encourages proposals: (a) to translate academic research discoveries with the goal of identifying more advanced therapeutic candidates, and (b) to conduct “proof-of-concept” testing of therapeutic candidates in relevant animal models or in man. It is intended that the IDDP Program will present an opportunity for JDRF to foster long-term collaborative relationships with industry, taking promising research through discovery and development, and toward commercialization. JDRF encourages companies proposing collaboration with academic researchers.

IDDP Program Structure

JDRF is prepared to fund applied research programs at both the preclinical and clinical stages of development. It is expected that collaborating companies must demonstrate a matching resource commitment to the

proposed program that is equal to or greater than that requested from JDRF. JDRF funded companies will be expected to enter into a research agreement with JDRF regarding milestones to be met in relation to anticipated funding, intellectual property, and JDRF participation in value creation. These will be negotiated on a case-by-case basis.

IDDP Therapeutic Pipeline



IDDP Application Process

JDRF encourages interested companies to initially contact Dr. Richard Insel, Executive Vice President of Research at rinsel@jdrf.org. Formal IDDP applications must be preceded by a letter of intent (LOI). Both LOIs and applications will be reviewed on a rolling basis. Please visit our website for more information: www.jdrf.org/industry_portfolio